Skip to content

Celcuity CELC Additional Paid-In Capital

Additional Paid-In Capital at other companies

Eli Lilly logo
Eli LillyLLY
$6.92B+0.2%
Gilead Sciences logo
Gilead SciencesGILD
$9.31B+14.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.11B+9.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$2.73B+7.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.83B+75.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.04B+46.9%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's additional paid-in capital?
Celcuity (CELC) reported additional paid-in capital of $555.22M in Q1 2026.
How has Celcuity's additional paid-in capital changed year-over-year?
Celcuity's additional paid-in capital increased by 40.4% year-over-year, from $395.48M to $555.22M.
What is the long-term trend for Celcuity's additional paid-in capital?
Over 5 years (2020 to 2025), Celcuity's additional paid-in capital has grown at a 70.6% compound annual growth rate (CAGR), from $38.01M to $549.4M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.